Proffered Paper - Investigational immunotherapy

LINK to Proffered Paper - Investigational immunotherapy

LINK to STREAM (needs an ESMO registration)

LBA41 - LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours

The abstract concludes: Len + pembro showed promising antitumor activity and manageable toxicity across the previously treated tumor cohorts evaluated in LEAP-005. The study is ongoing; all cohorts will expand to enroll ≤100 pts/cohort.

Read also ESMO's Daily Reporter News:

Lenvatinib Plus Pembrolizumab Extends Promise of Benefit to a Range of Solid Tumours


1019O - Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)

The abstract concludes: Sym021, Sym022 and Sym023 alone and Sym021 in combination with either Sym022 or Sym023 were well tolerated with AE profiles typical of immune checkpoint inhibitors. Responses were observed with single agent Sym021 and Sym022, and with both combinations. Evaluation of the antitumor activity of Sym021+022 and Sym021+023 doublets in select tumor types post-PD-(L)1 treatment is planned.


1020O - A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours

The abstract concludes: MGD019 has demonstrated an acceptable safety profile and encouraging early evidence of anti-tumor activity.


1021O - Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies

The abstract concludes: The initial results from Study AK104-101 suggest that AK104 is well-tolerated and possesses encouraging antitumor activity against mesothelioma. AK104 for the treatment of mesothelioma should be further evaluated.